In This Article:
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
These trade-offs can cause headaches for even the most seasoned professionals, which is why we started StockStory - to help you separate the good companies from the bad. Keeping that in mind, here is one small-cap stock that could be the next 100 bagger and two best left ignored.
Two Small-Cap Stocks to Sell:
Boston Beer (SAM)
Market Cap: $2.67 billion
Known for its flavorful beverages challenging the status quo, Boston Beer (NYSE:SAM) is a pioneer in craft brewing and a symbol of American innovation in the alcoholic beverage industry.
Why Are We Hesitant About SAM?
-
Lackluster 1.7% annual revenue growth over the last three years indicates the company is losing ground to competitors
-
Modest revenue base of $2.04 billion gives it less fixed cost leverage and fewer distribution channels than larger companies
-
Projected sales are flat for the next 12 months, implying demand will slow from its three-year trend
At $244.86 per share, Boston Beer trades at 24.2x forward P/E. Check out our free in-depth research report to learn more about why SAM doesn’t pass our bar.
ICU Medical (ICUI)
Market Cap: $3.52 billion
Founded in 1984 and named for its initial focus on intensive care units, ICU Medical (NASDAQ:ICUI) develops and manufactures medical products for infusion therapy, vascular access, and vital care applications used in hospitals and other healthcare settings.
Why Does ICUI Worry Us?
-
Annual revenue growth of 2.2% over the last two years was below our standards for the healthcare sector
-
Sales are projected to tank by 10.3% over the next 12 months as demand evaporates
-
Earnings per share were flat over the last five years while its revenue grew, showing its incremental sales were less profitable
ICU Medical’s stock price of $154.89 implies a valuation ratio of 19.8x forward P/E. Read our free research report to see why you should think twice about including ICUI in your portfolio, it’s free.
One Small-Cap Stock to Buy:
Hims & Hers Health (HIMS)
Market Cap: $11.5 billion
Originally launched with a focus on stigmatized conditions like hair loss and sexual health, Hims & Hers Health (NYSE:HIMS) operates a consumer-focused telehealth platform that connects patients with healthcare providers for prescriptions and wellness products.
Why Is HIMS a Good Business?
-
Customer growth averaged 48.6% over the past two years, showing its ability to "land" new contracts and potentially "expand" them later - a powerful one-two punch for sales
-
Earnings growth has trumped its peers over the last five years as its EPS has compounded at 28.6% annually
-
Free cash flow margin increased by 23.5 percentage points over the last five years, giving the company more capital to invest or return to shareholders